A specialized blood test can identify the presence of tumor cells in their earliest possible stage, is far less invasive than a traditional tissue biopsy, and can be used for both screening and surveillance. Developed by Naveris, the assay is showing promising results among Mount Sinai patients with HPV-related head and neck cancers.
